Adial Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-8.0M | $-13.2M | $-5.1M | $-12.7M | $-19.4M | $-10.9M | $-8.6M | $-11.6M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $565 | $565 | $564 | $564 | $565 | $564 | $565 | $563 |
| Stock-Based Compensation | $676.2K | $796.8K | $1.7M | $3.4M | $4.2M | $2.0M | $1.6M | $5.4M |
| Net Cash from Operating Activities | $-6.5M | $-6.9M | $-6.8M | $-11.2M | $-11.9M | $-7.6M | $-6.3M | $-2.5M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | $64.6K | — | — | — |
| Business Acquisitions | — | — | — | — | $-30.6K | — | — | — |
| Net Cash from Investing Activities | $150.0K | — | $1.5M | — | $-34.0K | $-350.0K | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | $1.7K | — | — | — | — | — |
| Net Cash from Financing Activities | $8.5M | $7.8M | $4.1M | $9.1M | $13.6M | $5.6M | $9.2M | $6.3M |
| Net Change in Cash | — | — | — | — | — | $-2.4M | $2.9M | $3.9M |
| Free Cash Flow | — | — | — | — | $-12.0M | — | — | — |